CRI:NYSECarter's, Inc. Analysis
Data as of 2026-05-22 - not real-time
$37.56
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Carter's posted Q1 FY2026 sales up 8.1% YoY to $681.1 million, beating consensus and delivering non‑GAAP EPS of $0.39. The stock trades at $37.56, roughly 8% below the analyst median target of $40.5, implying modest upside. However, the DCF fair value of $27.8 suggests the market may be pricing in premium expectations. Technicals show the price comfortably above the 20‑day and 50‑day SMAs (35.34 and 35.59), with a bullish MACD histogram and an RSI of 58, indicating neutral‑to‑positive momentum. Volume has been trending down, and the 30‑day volatility is elevated at 58%, flagging higher short‑term price swings. The company’s dividend yield of 2.66% and a payout ratio of 40% are supported by $95 million of free cash flow and a solid cash balance of $473 million. Debt remains high, with a debt‑to‑equity of 129%, but the leverage is offset by consistent operating cash flow and a ROE of 10.2%. Gross margin sits at 44.7% and operating margin at 4.2%, reflecting stable profitability in a competitive apparel segment. The beta of roughly 1.2 and the consumer‑cyclical nature of the business add medium‑to‑high market sensitivity. The current support at $32.16 and resistance near $39.47 give a clear trading range for the near term. Overall, the blend of earnings beat, dividend appeal, and modest target upside supports a positive bias, while valuation and leverage temper enthusiasm. Investors should weigh the short‑term upside against the elevated volatility and long‑term debt profile before adjusting positions.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Q1 earnings beat expectations
- Price above 20‑day and 50‑day SMAs with bullish MACD
- Support level provides downside cushion
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Analyst median target suggests ~7% upside
- Sustainable dividend yield of 2.66%
- Revenue growth of 8% YoY
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- High debt‑to‑equity ratio raises leverage risk
- Valuation split between DCF undervaluation and market premium
- Consumer‑cyclical exposure adds sector volatility
Key Metrics & Analysis
Financial Health
Revenue Growth8.10%
Profit Margin3.07%
P/E Ratio15.1
ROE10.20%
ROA3.80%
Debt/Equity128.85
P/B Ratio1.5
Op. Cash Flow$177.4M
Free Cash Flow$95.2M
Technical Analysis
TrendNeutral
RSI58.2
Support$32.16
Resistance$39.47
MA 20$35.34
MA 50$35.59
MA 200$33.01
MACDBullish
VolumeDecreasing
Fear & Greed Index91.5
Valuation
Fair Value$27.81
Target Price$40.67
Upside/Downside8.27%
GradeFair
TypeBlend
Dividend Yield2.66%
Risk Assessment
Beta1.20
Volatility58.54%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.